USPTO serial 98304980
OCELLOS
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- CROWDER-SCHAEFER, ANDREW W
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with OCELLOS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Bradley M. Stohry
Bradley M. Stohry REICHEL STOHRY DEAN LLP6151 CENTRAL AVEINDIANAPOLIS, IN 46220United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 009 | Downloadable software for use and integration in supply chain management related to cell and gene therapy and advanced therapies; Downloadable software for use in managing data for clinical trials; Downloadable software for chain of identity and chain of custody management in clinical trials and commercialization of medical therapies; Downloadable software for use in drug therapy development; Downloadable software for data analysis and reporting in the field of clinical trials and commercialization of medical therapies using artificial intelligence; Downloadable software for the provision of healthcare in the nature of providing medical diagnosis using artificial intelligence; Downloadable software for use in cell and gene therapy orchestration; Downloadable software for use in inventory management for scheduling and planning pharmaceutical resources; Downloadable software for use in control and tracking of cell and gene therapy products | ACTIVE | — |
| 041 | Arranging and conducting of training courses in the field of cell and gene therapy; Arranging and conducting of training workshops in the field of operation and development of software systems; Arranging and conducting of training workshops in the field of cell and gene therapy; Training services in the field of cell and gene therapy | ACTIVE | — |
| 042 | Platform as a service (PAAS) featuring computer software platforms for use and integration in supply chain management related to cell and gene therapy and advanced therapies; Platform as a service (PAAS) featuring computer software platforms for use in managing data for clinical trials; Platform as a service (PAAS) featuring computer software platforms for chain of identity and chain of custody management in clinical trials and commercialization of medical therapies; Platform as a service (PAAS) featuring computer software platforms for use in drug therapy development; Platform as a service (PAAS) featuring computer software platforms for data analysis and reporting in the field of clinical trials and commercialization of medical therapies using artificial intelligence; Platform as a service (PAAS) featuring computer software platforms for use in the provision of healthcare in the nature of providing medical diagnosis using artificial intelligence; Platform as a service (PAAS) featuring computer software platforms for use in cell and gene therapy orchestration; Platform as a service (PAAS) featuring computer software platforms for use in inventory management for scheduling and planning pharmaceutical resources; Platform as a service (PAAS) featuring computer software platforms for use in control and tracking of cell and gene therapy products; Software as a service (SAAS) services featuring software platforms for use and integration in supply chain management related to cell and gene therapy and advanced therapies; Software as a service (SAAS) services featuring software for use in managing data for clinical trials; Software as a service (SAAS) services featuring software for chain of identity and chain of custody management in clinical trials and commercialization of medical therapies; Software as a service (SAAS) services featuring software for use in drug therapy development; Software as a service (SAAS) services featuring software for data analysis and reporting in the field of clinical trials and commercialization of medical therapies using artificial intelligence; Software as a service (SAAS) services featuring software for use in the provision of healthcare in the nature of providing medical diagnosis using artificial intelligence; Software as a service (SAAS) services featuring software for use in cell and gene therapy orchestration; Software as a service (SAAS) services featuring software for use in pharmacy inventory management for scheduling and planning pharmaceutical resources; Software as a service (SAAS) services featuring software for use in control and tracking of cell and gene therapy products; Providing temporary use of non-downloadable cloud-based software for use and integration in supply chain management related to cell and gene therapy and advanced therapies; Providing temporary use of non-downloadable cloud-based software for use in managing data for clinical trials; Providing temporary use of non-downloadable cloud-based software for chain of identity and chain of custody management in clinical trials and commercialization of medical therapies; Providing temporary use of non-downloadable cloud-based software for use in drug therapy development; Providing temporary use of non-downloadable cloud-based software for data analysis and reporting in the field of clinical trials and commercialization of medical therapies using artificial intelligence; Providing temporary use of non-downloadable cloud-based software for use in the provision of healthcare in the nature of providing medical diagnosis using artificial intelligence; Providing temporary use of non-downloadable cloud-based software for use in cell and gene therapy orchestration; Providing temporary use of non-downloadable cloud-based software for use in pharmacy inventory management for scheduling and planning pharmaceutical resources; Providing temporary use of non-downloadable cloud-based software for use in control and tracking of cell and gene therapy products | ACTIVE | — |
| 045 | Licensing of intellectual property in the field of cell and gene therapy; Software licensing; Granting of software licences | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by TrakCel Limited
- Other trademarks owned by TrakCel Limited
- Other trademarks in Class 009
- Other trademarks in Class 041
- Other trademarks in Class 042
- Other trademarks in Class 045
- Similar marks named OCELLOS
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 6, 2026 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Apr 6, 2026 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Sep 15, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Sep 4, 2025 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Sep 4, 2025 | EXT1 | SOU EXTENSION 1 FILED | — |
| Sep 4, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 4, 2025 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jan 7, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 7, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 1, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Dec 10, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 10, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 10, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 10, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 17, 2024 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 17, 2024 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 17, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 9, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 25, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 12, 2023 | NWAP | NEW APPLICATION ENTERED | — |